Notice of Pre-AIA or AIA Status
The present application, filed on or after
March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claims 1-5, 7, 9-11, 13, 17, 18, 23-25, 27, 31, 32, 36 and 37 are pending in the instant application.
Election/Restrictions
Applicant’s election without traverse of Group I,
PNG
media_image1.png
204
602
media_image1.png
Greyscale
,
and the species of the compound of Formula 4a,
PNG
media_image2.png
110
170
media_image2.png
Greyscale
,
in the reply filed on June 11, 2026 is acknowledged.
The requirement is still deemed proper and is therefore made FINAL.
Claims 10, 11, 13, 17, 18, 23-25, 27, 31, 32, 36 and 37 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on June 11, 2026.
It is suggested that in order to advance prosecution, the non-elected subject matter in which rejoinder is not applicable (i.e., the claims of non-elected Groups II-IV) be canceled if Applicant files a response to this Office Action.
Priority
Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55.
Information Disclosure Statement
The Examiner has considered the Information Disclosure Statement filed on May 8, 2023. The submission is in compliance with the provisions of
37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Claim Objections
Claim 1 is objected to because of the following informalities: in claim 1, under the definition of variable R1, an “and” should be added between “-COR3,” and “CO2R3,” (the 4th line from the end of the claim).
Appropriate correction is required.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-5, 7 and 9 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 4-11 and 15-25 of copending Application No. 19/161,127 (reference application), US 2026/0242370. Although the claims at issue are not identical, they are not patentably distinct from each other because copending Application No. 19/161,127 claims a process for making an aza-bicyclic compound of Formula 1,
PNG
media_image3.png
94
110
media_image3.png
Greyscale
, comprising reacting a nortropinone compound of Formula 2,
PNG
media_image4.png
88
106
media_image4.png
Greyscale
, with a halogenated compound of Formula 3,
PNG
media_image5.png
54
78
media_image5.png
Greyscale
. The Specification on page 47 of copending Application No. 19/161,127 discloses a reaction which is embraced by its claims in Scheme 1,
PNG
media_image6.png
132
544
media_image6.png
Greyscale
The instant application and copending Application No. 19/161,127 share the same assignee. The instant application is not related to copending Application No. 19/161,127 and thus, no 35 USC 121 shield exists here. See MPEP 804.01. Therefore, the claims in copending Application No. 19/161,127 anticipate and/or render obvious the instant claimed invention.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-5 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Webster et al. {U.S. Patent 9,365,564}.
Applicant claims a process for preparing an aza-bicyclic compound of Formula 4,
PNG
media_image7.png
96
136
media_image7.png
Greyscale
, comprising a Grignard reaction of a nortropinone compound of Formula 5,
PNG
media_image8.png
100
122
media_image8.png
Greyscale
, with a halogenated compound of Formula 6,
PNG
media_image9.png
56
92
media_image9.png
Greyscale
,
wherein R1 can represent an unsubstituted or substituted
monocyclic heterocyclyl, which monocyclic
heterocyclyl can be aromatic (such as pyrazine and
pyrimidine);
R2 represents an amine protecting group (such as a
benzyl or a tert-butyloxycarbonyl group); and
X represents a halogen.
Webster et al. disclose, for instance, Synthesis 15 (columns 84-85) and Synthesis 31 (column 96),
PNG
media_image10.png
222
272
media_image10.png
Greyscale
PNG
media_image11.png
196
218
media_image11.png
Greyscale
PNG
media_image12.png
536
470
media_image12.png
Greyscale
.
Therefore, Webster et al. anticipate the instant claimed invention.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1-5 and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Webster et al. {U.S. Patent 9,365,564}, taken alone, and in further view of Delia {Journal of Heterocyclic Chemistry, 50(4), July 2013, pages 735-745}.
Determination of the scope and content of the prior art (MPEP §2141.01)
Applicant claims a process for preparing an aza-bicyclic compound of Formula 4,
PNG
media_image7.png
96
136
media_image7.png
Greyscale
, comprising a Grignard reaction of a nortropinone compound of Formula 5,
PNG
media_image8.png
100
122
media_image8.png
Greyscale
, with a halogenated compound of Formula 6,
PNG
media_image9.png
56
92
media_image9.png
Greyscale
,
wherein R1 can represent an unsubstituted or substituted
monocyclic heterocyclyl (such as pyrazine and
pyrimidine);
R2 represents an amine protecting group (such as a
benzyl or a tert-butyloxycarbonyl group); and
X represents a halogen.
Webster et al. teach processes for producing aza-bicyclic compounds (such as
PNG
media_image13.png
208
204
media_image13.png
Greyscale
,
PNG
media_image14.png
292
274
media_image14.png
Greyscale
and
PNG
media_image15.png
242
280
media_image15.png
Greyscale
) in which a nitrogen protected nortropinone compound (such as
PNG
media_image16.png
202
150
media_image16.png
Greyscale
and
PNG
media_image17.png
198
154
media_image17.png
Greyscale
) is used as the starting material. Webster et al. disclose, for instance, Synthesis 15 (columns 84-85) and Synthesis 31 (column 96),
PNG
media_image10.png
222
272
media_image10.png
Greyscale
PNG
media_image11.png
196
218
media_image11.png
Greyscale
PNG
media_image12.png
536
470
media_image12.png
Greyscale
.
Ascertainment of the difference between the prior art and the claimed invention (MPEP §2141.02)
The difference, if any, between the processes of Webster et al. and the process instantly claimed, especially in instant claim 9, is that of analogous reactants/starting materials.
Finding of prima facie obviousness--rational and motivation
(MPEP §2142-2143)
However, Synthesis 3 (column 74) in Webster et al. prepares the product of instant Formula 4a,
PNG
media_image18.png
110
170
media_image18.png
Greyscale
, stated in instant claim 9. Synthesis 15 (columns 84-85) and Synthesis 17 (column 85) in Webster et al. teach that iodine can be used as the halogen in the starting material of instant Formula 6 in instant claim 1. Further, Delia discloses Compound 37,
PNG
media_image19.png
134
94
media_image19.png
Greyscale
, in Scheme 11 on page 737, which is the compound of instant Formula 6a,
PNG
media_image20.png
96
98
media_image20.png
Greyscale
, in instant claim 9. Synthesis 3 (column 74) and Synthesis 31 (column 96) in Webster et al. teach the tropinone compound of instant Formula 5a,
PNG
media_image21.png
98
124
media_image21.png
Greyscale
, in instant claim 9 and that said tropinone compound can be used as a starting material in the process.
The use of analogous reactants in a known process is prima facie obvious. In re Durden, 226 USPQ 359 (Fed. Cir. 1985). Once the general reaction has been shown to be old, the burden is on Applicants to present reasons or authority for believing that a group on the starting material would take part in or affect the basic reaction and thus alter the nature of the product or the operability of the process. In looking at the instant claimed process as a whole, as stated in In re Ochiai, 37 USPQ2d 1127 (Fed. Cir. 1995), the claimed process would have been suggested to one skilled in the art.
Note to Applicant: Not every piece of prior art found in the database search or class/subclass search which would anticipate and/or render obvious the instant claimed invention under examination has been applied against the instant currently pending claims under examination. See MPEP 904.03.
Reminder to Applicant
As a reminder, Applicant should specifically point out the support in the original disclosure {i.e., page number(s) and line number(s)} for any new claims or amended claims and for any amendments made to the disclosure. Making generic statements such as “all amendments are fully supported in the originally filed disclosure or the originally filed claims” without specifying page numbers and originally filed claim numbers are insufficient. See MPEP §714.02 and MPEP §2163.06(I).
Telephone Inquiry
Any inquiry concerning this communication or earlier communications from the examiner should be directed to:
Laura L. Stockton
(571) 272-0710.
The examiner can normally be reached on Monday-Friday from 8:30 am to 6 pm, Eastern Standard Time.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s acting supervisor,
James Alstrum-Acevedo can be reached on 571/272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/LAURA L STOCKTON/ Primary Examiner, Art Unit 1626 Work Group 1620
Technology Center 1600
August 26, 2026
Book XXIX, page 55